A Method for Creating Myeloid Cell Lines
Background
- Acute myeloid leukemia is the most common leukemia in adults, the second most common leukemia in children and has a significantly worse prognosis than other leukemias.
- Understanding myelopoiesis and developing methods of modulating myelopoiesis are of importance.
- It is of particular importance to develop methods of modulating immune disorders.
- Development of myeloid cell lines capable of differentiation or proliferation is of importance in increasing knowledge of myelopoiesis, developing methods of modulating myelopoiesis and modulating immune disorders particularly myeloid disorders, more particularly leukemias.
- The transcription factor PU.1 is a tissue specific ETs-family member that is expressed in various lineages of hematopoietic cells.
- PU.1 functions in granulocytes, macrophages, and B lymphocytes and is required for development of both myeloid and lymphoid lineages.
- EVI-1 is a zinc-finger transcriptional regulator that promotes myeloid cell proliferation and is implicated in acute myeloid leukemia, the blast crisis of chronic myelogenous leukemia and myelodysplastic syndromes.
Current Invention
Research at Cincinnati Children's Research Foundation in the laboratory of Dr. Bruce Trapnell has resulted in the creation of myeloid cell lines and models of immune disorders, particularly myeloid disorders. The technology is based upon the observation that EVI-1 and PU.1 constitute a molecular switch. The interplay between EVI-1 and PU.1 regulates the transition from the anchorage-independent proliferation of undifferentiated macrophage lineage cells to terminally differentiated macrophages with reduced rate of proliferation. Using defined expression cassettes operably linked to EVI-1 and PU.1 in cell culture and in transgenic animals, the technology provides methods of modulating differentiation of myeloid cells, thus providing as assay system for compounds to treat immune disorders, particularly a myeloid disorder such leukemia. Further research continues to explore the details of this technology. A patent application has been filed on this technology.
Objective
Cincinnati Children's Research Foundation is seeking a corporate partner for the further development of this technology and the use of this technology for the identification of novel compounds to treat leukemias.
Contact
To discuss this opportunity further and/or to receive confidential and proprietary information relating to this technology, please contact:
Joseph D. Fondacaro, PhD
Director, Office of Intellectual Property & Venture Development
Cincinnati Children's Research Foundation
Mail Location 7032
3333 Burnet Avenue
Cincinnati, Ohio 45229-3039
Phone: 513-636-7695
Fax: 513-636-8453
Email: jdfonda@cchmc.org
| Related Study Information |
|---|
| You must have the free Adobe Acrobat" Reader software installed on your computer to read this file. You can download Adobe Acrobat" Reader at Adobe's web site by selecting the version appropriate for your type of computer. |
